---
title: "Magnetic Nanoparticles for Cancer Imaging and Theranostics: SPION and USPION Advances"
id: "pubmed-42551722"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42551722"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42551722/"
doi: "10.1016/j.ijpharm.2026.127261"
published_at: "2026-09-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Magnetic Nanoparticles for Cancer Imaging and Theranostics: SPION and USPION Advances
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42551722
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42551722/)
- **DOI:** [10.1016/j.ijpharm.2026.127261](https://doi.org/10.1016%2Fj.ijpharm.2026.127261)
- **Published At:** 2026-09-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Cancer treatment is limited by poor specificity of chemotherapeutic and imaging agents, causing reduced efficacy and high systemic toxicity. - **Magnetic nanoparticles (MNPs)**, notably **Superparamagnetic Iron Oxide Nanoparticles (SPION)** and **Ultrasmall SPION (USPION)**, offer theranostic potential due to magnetic responsiveness and biocompatibility. - Iron oxide materials such as **Fe3O4 (magnetite)** and maghemite (γ-Fe2O3) can integrate imaging, targeting, hyperthermia, and drug delivery in a single platform. - Recent progress covers synthesis methods, surface modification with biocompatible polymers and targeting ligands, and physicochemical characterization to optimize biological performance. - Targeting and controlled delivery strategies highlighted include magnetic field–guided localization, stimuli-responsive drug release, ligand-mediated targeting, and multifunctional nanocarrier design. - Advances in **magnetic resonance imaging (MRI)**, image-guided therapy, multimodal therapy, and clinically relevant theranostic applications are summarized and critically discussed. - Translation challenges remain significant: scale-up, long-term safety, regulatory hurdles, and clinical translation pathways were identified as current obstacles. - Authors conclude that SPION- and USPION-based magnetic nanoplatforms are a promising route to precision oncology by combining diagnostic, therapeutic, and monitoring functions in one nanoplatform to support personalized cancer treatment.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42551722/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42551722%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42551722/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42551722/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42551722/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42551722/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42551722/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42551722%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42551722%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42551722/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42551722/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42551722/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42551722/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0378-5173\(26\)00709-X "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42551722/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42551722/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42551722/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42551722/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42551722/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42551722/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42551722/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42551722/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42551722/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42551722/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42551722/#linkout) Title & authors Abstract Conflict of interest statement Similar articles Publication types MeSH terms Substances Related information LinkOut - more resources Review Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) . 2026 Sep 5:702:127261. doi: 10.1016/j.ijpharm.2026.127261. Epub 2026 Aug 4. # Breaking the delivery barrier: magnetic nanoparticles at the Nexus of imaging and theranostics [Rajesh Singh](https://pubmed.ncbi.nlm.nih.gov/?term=Singh+R&cauthor_id=42551722)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42551722/#full-view-affiliation-1 "Research and Development Laboratory, Ananta Medicare Ltd., Sri Ganganagar, Rajasthan 335002, India."), [Smita Jain](https://pubmed.ncbi.nlm.nih.gov/?term=Jain+S&cauthor_id=42551722)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42551722/#full-view-affiliation-2 "Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: smitajain1994@gmail.com."), [Ashwini Kumar Mishra](https://pubmed.ncbi.nlm.nih.gov/?term=Mishra+AK&cauthor_id=42551722)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42551722/#full-view-affiliation-3 "Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: ashwinik757@gmail.com.") Affiliations Expand ### Affiliations * 1 Research and Development Laboratory, Ananta Medicare Ltd., Sri Ganganagar, Rajasthan 335002, India. * 2 Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: smitajain1994@gmail.com. * 3 Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: ashwinik757@gmail.com. * PMID: **42551722** * DOI: [ 10.1016/j.ijpharm.2026.127261 ](https://doi.org/10.1016/j.ijpharm.2026.127261) Item in Clipboard Review # Breaking the delivery barrier: magnetic nanoparticles at the Nexus of imaging and theranostics Rajesh Singh et al. Int J Pharm. 2026. Show details Display options Display options Format Abstract PubMed PMID Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) . 2026 Sep 5:702:127261. doi: 10.1016/j.ijpharm.2026.127261. Epub 2026 Aug 4. ### Authors [Rajesh Singh](https://pubmed.ncbi.nlm.nih.gov/?term=Singh+R&cauthor_id=42551722)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42551722/#short-view-affiliation-1 "Research and Development Laboratory, Ananta Medicare Ltd., Sri Ganganagar, Rajasthan 335002, India."), [Smita Jain](https://pubmed.ncbi.nlm.nih.gov/?term=Jain+S&cauthor_id=42551722)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42551722/#short-view-affiliation-2 "Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: smitajain1994@gmail.com."), [Ashwini Kumar Mishra](https://pubmed.ncbi.nlm.nih.gov/?term=Mishra+AK&cauthor_id=42551722)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42551722/#short-view-affiliation-3 "Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: ashwinik757@gmail.com.") ### Affiliations * 1 Research and Development Laboratory, Ananta Medicare Ltd., Sri Ganganagar, Rajasthan 335002, India. * 2 Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: smitajain1994@gmail.com. * 3 Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India. Electronic address: ashwinik757@gmail.com. * PMID: **42551722** * DOI: [ 10.1016/j.ijpharm.2026.127261 ](https://doi.org/10.1016/j.ijpharm.2026.127261) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Cancer is still one of the major causes of death globally, and the lack of specificity of current chemotherapeutic and imaging agents still remains to be a major issue in the therapy of cancer, which lead to the lack of efficacy and high systemic toxicity. Magnetic nanoparticles (MNPs) especially Superparamagnetic Iron Oxide Nanoparticles (SPION) and Ultrasmall Superparamagnetic Iron Oxide Nanoparticles (USPION) have shown potential as theranostic platforms due to their magnetic responsiveness, biocompatibility, and multiple functionalities. The advantages of iron oxide-based nanomaterials such as Fe3O4 (magnetite) and maghemite (γ-Fe2O3) are that multiple imaging, targeting, hyperthermia and drug delivery modalities can be integrated into a single material, allowing for improved antitumoral efficacy while reducing off-target toxicity. The recent progress in the synthesis, surface modification of magnetic nanoparticles with biocompatible polymers and targeting ligands, and their physicochemical characterization, for optimization of biological performance, is summarised. Special attention is given to the strategies for targeted and controlled delivery such as magnetic field guided localization, stimuli responsive drug release, ligand mediated targeting, and multifunctional nanocarrier design. Additionally, recent advances in magnetic resonance imaging (MRI), image-guided therapy, multimodal therapy and clinically relevant theranostic applications are critically discussed. Current challenges in translation are also discussed, such as scale-up, long-term safety, regulatory aspects and clinical translation. In conclusion, the magnetic nanoplatforms based on SPIONs and USPIONs are a very promising approach to precision oncology, combining diagnostic, therapeutic and monitoring functions in a single nanoplatform, which will facilitate the translation of magnetic nanomedicine toward personalized cancer treatment. **Keywords:** Anti-tumoral; Fe(3)O(4); Maghemite; Superparamagnetic Iron Oxide Nanoparticles (SPION); Targeted and controlled delivery; Ultrasmall Superparamagnetic Iron Oxide Nanoparticles (USPION). Copyright © 2026 Elsevier B.V. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Iron-Based Nanoparticles as Delivery Tools. ](https://pubmed.ncbi.nlm.nih.gov/42198329/) Parang K, Vadlapatla R, Koomer A, Moran V, Jackson L, Shirazi AN.Parang K, et al.Pharmaceuticals (Basel). 2026 Apr 22;19(5):654. doi: 10.3390/ph19050654.Pharmaceuticals (Basel). 2026.PMID: 42198329Free PMC article.Review. * [ Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. ](https://pubmed.ncbi.nlm.nih.gov/27876448/) Zhu L, Zhou Z, Mao H, Yang L.Zhu L, et al.Nanomedicine (Lond). 2017 Jan;12(1):73-87. doi: 10.2217/nnm-2016-0316. Epub 2016 Nov 23.Nanomedicine (Lond). 2017.PMID: 27876448Free PMC article.Review. * [ Fe3O4-based nanotheranostics for magnetic resonance imaging-synergized multifunctional cancer management. ](https://pubmed.ncbi.nlm.nih.gov/31215317/) Li Y, Zhang H.Li Y, et al.Nanomedicine (Lond). 2019 Jun;14(11):1493-1512. doi: 10.2217/nnm-2018-0346. Epub 2019 Jun 19.Nanomedicine (Lond). 2019.PMID: 31215317Review. * [ Review of engineered magnetic chitosan nanoparticles for drug delivery: Advances, challenges, and future prospects. ](https://pubmed.ncbi.nlm.nih.gov/40925426/) Pareek A, Alasiri G, Dudhwala Y, Alaseem AM, Alsaidan OA, Kapoor DU, Prajapati BG.Pareek A, et al.Int J Biol Macromol. 2025 Oct;327(Pt 2):147441. doi: 10.1016/j.ijbiomac.2025.147441. Epub 2025 Sep 7.Int J Biol Macromol. 2025.PMID: 40925426Review. * [ Magnetic nanoparticles as promising materials for the future of medicine. ](https://pubmed.ncbi.nlm.nih.gov/41661353/) Najafi F, Maleki-Hajiagha A, Farsani NK, Tavakkol M, Sharma A, Sheykholeslami SE, Farahmand F, Kazemi Z, Katebi A, Farmani AR, Chalati T.Najafi F, et al.J Mater Sci Mater Med. 2026 Feb 9;37(1):37. doi: 10.1007/s10856-025-06981-5.J Mater Sci Mater Med. 2026.PMID: 41661353Free PMC article.Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42551722) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Antineoplastic Agents / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fadministration+and+dosage%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Drug Delivery Systems* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Delivery+Systems%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Delivery+Systems) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Magnetic Iron Oxide Nanoparticles* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Magnetic+Iron+Oxide+Nanoparticles%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Magnetic+Iron+Oxide+Nanoparticles) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Magnetic Resonance Imaging Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Magnetic+Resonance+Imaging%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Magnetic+Resonance+Imaging) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Magnetite Nanoparticles* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Magnetite+Nanoparticles%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Magnetite+Nanoparticles) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Magnetite Nanoparticles* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Magnetite+Nanoparticles%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Magnetite+Nanoparticles) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Neoplasms* / diagnostic imaging Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fdiagnostic+imaging%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Theranostic Nanomedicine* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Theranostic+Nanomedicine%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Theranostic+Nanomedicine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) ## Substances * Magnetite Nanoparticles Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Magnetite+Nanoparticles%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Magnetite+Nanoparticles%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) * Antineoplastic Agents Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antineoplastic+Agents%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42551722/) ## Related information * [ Me
## Related Clinical Research

- [miRNA Diagnostic Accuracy for Upper Aerodigestive Tract Malignancies: Systematic Review Protocol](https://medichelpline.com/clinical-feed/bmj-open-7-diagnostic-accuracy-of-mirna-in-detection-of-upper-aerodigestive-tract.md)
- [Retraction notice: concerns over figures in study on CCDC6 sumoylation and CREB1 regulation](https://medichelpline.com/clinical-feed/plos-one-15-retraction-identification-of-sumoylation-sites-in-ccdc6-the-first-identified.md)
- [CDCTNet: Transformer–CNN hybrid for colorectal lesion diagnosis](https://medichelpline.com/clinical-feed/plos-one-7-colorectal-lesion-diagnosis-using-transformer-and-deep-learning-with-multiscale.md)
- [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)
- [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.